Clinical Trial

Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway

Name: Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway — clinical trial record (NCT07629167)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PNOC039

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A phase 2 study testing the efficacy of isotretinoin versus doxycycline in treating participants who develop a acneiform rash caused by standard of care, tumor-directed therapies targeting the mitogenactivated protein kinase (MAPK) pathway.

Trial Details

NCT Number	NCT07629167
Lead Sponsor	University of California, San Francisco Collaborators: Day One Biopharmaceuticals, Inc.
Conditions	Acneiform Drug Eruption, Acneiform Eruptions
Enrollment	50 participants
Start Date	2026-08-30
Primary Completion	2029-08-30 (estimated)
Study Completion	2030-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-05